Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 367
Filter
1.
Article in Chinese | WPRIM | ID: wpr-927999

ABSTRACT

This study aims to evaluate the methodological and reporting quality of diagnosis and treatment guidelines for hyperuricemia as well as the expert consensuses and promote the understanding and application of the diagnosis and treatment guidelines for hyperuricemia. With "hyperuricemia" "guidelines" "consensus" "recommendations" as the key words in titles, the authors searched for the published clinical guidelines on hyperuricemia in Chinese against CNKI, Wanfang, VIP, Medlive and the official website of the industry association. The retrieval time limit was until May 31, 2021. The appraisal of guidelines for research and evaluation Ⅱ(AGREEⅡ) and the reporting items for practice guidelines in health care(RIGHT) were employed to evaluate the methodological quality and reporting quality of 14 guidelines/consensuses included. The average scores of the guidelines/consensuses were 80.85%(48.61%-98.61%) for the domain of scope and purpose, 34.52%(0-69.44%) for the domain of stakeholder involvement, 35.53%(6.25%-92.19%) for the domain of rigor of development, 55.85%(23.61%-86.11%) for the domain of clarity of presentation, 26.19%(0-76.04%) for the domain of applicability, and 21.42%(0-50.00%) for the domain of editorial independence. Nine guidelines/consensuses were of medium overall quality with grade B recommendation, and five guidelines/consensuses were of poor quality with grade C recommendation. The RIGHT classified the fourteen guidelines/consensuses into one of high reporting quality, three of medium reporting quality, and ten of low reporting quality. The results of this study indicate that the standardization and rigor of the methodological quality and the reporting quality of the clinical guidelines/consensuses for hyperuricemia in China remain to be strengthened.


Subject(s)
China , Consensus , Humans , Hyperuricemia/drug therapy , Publications , Reference Standards
2.
J. bras. nefrol ; 43(4): 572-579, Dec. 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1350906

ABSTRACT

Abstract Hyperuricemia is common in chronic kidney disease (CKD) and may be present in 50% of patients presenting for dialysis. Hyperuricemia can be secondary to impaired glomerular filtration rate (GFR) that occurs in CKD. However, hyperuricemia can also precede the development of kidney disease and predict incident CKD. Experimental studies of hyperuricemic models have found that both soluble and crystalline uric acid can cause significant kidney damage, characterized by ischemia, tubulointerstitial fibrosis, and inflammation. However, most Mendelian randomization studies failed to demonstrate a causal relationship between uric acid and CKD, and clinical trials have had variable results. Here we suggest potential explanations for the negative clinical and genetic findings, including the role of crystalline uric acid, intracellular uric acid, and xanthine oxidase activity in uric acid-mediated kidney injury. We propose future clinical trials as well as an algorithm for treatment of hyperuricemia in patients with CKD.


Resumo A hiperuricemia é comum na doença renal crônica (DRC) e pode estar presente em até 50% dos pacientes que se apresentam para diálise. A hiperuricemia pode ser secundária ao comprometimento da taxa de filtração glomerular (TFG) que ocorre na DRC. No entanto, ela também pode preceder o desenvolvimento da doença renal e mesmo prever uma DRC incidente. Estudos experimentais de modelos hiperuricêmicos descobriram que tanto o ácido úrico solúvel quanto o cristalino podem causar danos renais significativos, caracterizados por isquemia, fibrose tubulointersticial e inflamação. Entretanto, a maioria dos estudos de randomização Mendeliana falhou em demonstrar uma relação causal entre o ácido úrico e a DRC, e os ensaios clínicos têm apresentado resultados variáveis. Aqui sugerimos explicações potenciais para os achados clínicos e genéticos negativos, incluindo o papel do ácido úrico cristalino, do ácido úrico intracelular e da atividade da xantina oxidase na lesão renal mediada por ácido úrico. Propomos ensaios clínicos futuros, bem como um algoritmo para o tratamento de hiperuricemia em pacientes com DRC.


Subject(s)
Humans , Hyperuricemia/complications , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/therapy , Uric Acid , Renal Dialysis , Glomerular Filtration Rate
3.
Arq. bras. cardiol ; 117(2): 378-384, ago. 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1339152

ABSTRACT

Resumo Fundamento: A hiperuricemia é um achado frequente em pacientes com hipertensão arterial e há evidências cada vez maiores de que essa entidade seja também um fator de risco para doença cardiovascular. Objetivos: No contexto da população em processo de envelhecimento, este estudo tem o objetivo de avaliar níveis de ácido úrico sérico e a prevalência e o controle da hipertensão arterial em um subgrupo da população de adultos romenos (>65 anos), em relação à influência da idade nesses parâmetros. Métodos: A amostra do estudo consiste em 1920 adultos incluídos na pesquisa SEPHAR III, dos quais 447 eram pacientes idosos (>65 anos de idade). Durante as duas visitas do estudo, três aferições de pressão arterial (PA) foram realizadas em intervalos de 1 minuto, e foram realizadas medições de níveis de ácido úrico sérico, função renal por taxa de filtração glomerular, pressão arterial e espessura íntima-média. A hipertensão e os controles foram definidos de acordo com as diretrizes atuais. A avaliação da espessura íntima-média foi determinada pela avaliação por ultrassom Doppler modo B. Um nível de significância p < 0,05 foi adotado para a análise estatística. Resultados: Pacientes adultos tinham níveis de ácido úrico sérico significativamente mais baixos, se comparados a pacientes idosos, independentemente dos níveis de taxa de filtração glomerular. Pacientes adultos tinham níveis de espessura íntima-média, comparados a pacientes idosos. Conclusão: De forma semelhante às pesquisas anteriores, neste estudo, a idade representou um dos fatores contribuintes ao nível aumentado de ácido úrico sérico. Também foi obtido um aumento da prevalência da hipertensão arterial com a idade, com um mau controle da pressão arterial.


Abstract Background: Hyperuricemia is a frequent finding in patients with arterial hypertension, and there is increasing evidence that this entity is also a risk factor for cardiovascular disease. Objective: In the context of an aging population, this study aims to evaluate serum uric acid levels and arterial hypertension prevalence and control in a subgroup of Romanian adults (>65 years), concerning the influence of age on these parameters. Method: The study sample consists of 1,920 adults included in SEPHAR III survey, of whom 447 were elderly patients (>65 years of age). During the two study visits, three blood pressure (BP) measurements were performed at 1-min intervals and serum uric acid levels, kidney function by estimated glomerular filtration rate, blood pressure, and intima media thickness measurements were conducted. Hypertension and controls were defined according to the current guidelines. Intima-media thickness evaluation was assessed by B-mode Doppler ultrasound evaluation. A significance level p < 0.05 was adopted for the statistical analysis. Results: Adult patients had a significant lower serum uric acid levels, compared to elderly patients, regardless of glomerular filtration rate levels. Adult patients showed a significantly lower intima-media thickness levels, when compared to elderly patients. Conclusion: Similar to previous studies, in the present study, age represented one of the factors contributing to the increased level of serum uric acid. An increasing prevalence of arterial hypertension with age, together with a poor control of blood pressure, was also obtained.


Subject(s)
Humans , Adult , Aged , Hyperuricemia/epidemiology , Hypertension/epidemiology , Uric Acid , Blood Pressure , Risk Factors , Carotid Intima-Media Thickness
5.
Rev. Assoc. Med. Bras. (1992) ; 67(6): 828-832, June 2021. tab, graf
Article in English | LILACS | ID: biblio-1346904

ABSTRACT

SUMMARY OBJECTIVE: The aim of this study was to evaluate the association between hyperuricemia and systemic arterial hypertension. METHODS: This was a case-control study where individuals aged >18 years were included, who were divided into hypertensive and non-hypertensive groups, excluding those with incomplete information in medical records or with the chronic kidney disease epidemiology collaboration <60 mL/min/1.73 m³. Systemic arterial hypertension was categorized as a dependent variable, while the independent variables were hyperuricemia (i.e., primary variable), sex, education, the practice of physical activity, alcoholism, smoking, diabetes mellitus, chronic kidney disease, a family history of systemic arterial hypertension, age, isolated hyperlipidemia, and mixed hyperlipidemia. Statistical analysis included the univariate and multivariate data analysis, performed by adjusting the logistic regression models using the software R (R Core Team [2018]). RESULTS: Out of 103 patients evaluated, 75 patients were included in this study. In hypertensive patients, hyperuricemia was more frequent (p=0.029), being present in 18.9% individuals. In the univariate analysis, a statistically significant association was found between hyperuricemia and systemic arterial hypertension (OR 10.9; 95%CI 1.29-1420.0; p=0.023); however, in the multivariate analysis, when adjustment was made for age, the only control variable that persisted in the model, this association ceased to be significant (OR 8.5; 95%CI 0.87-1157.0; p=0.070). CONCLUSIONS: There was no independent association between hyperuricemia and systemic arterial hypertension. The latter was associated with diabetes mellitus, chronic kidney disease, and age.


Subject(s)
Humans , Hyperuricemia/complications , Hyperuricemia/epidemiology , Diabetes Mellitus , Hypertension/complications , Hypertension/epidemiology , Uric Acid , Case-Control Studies , Risk Factors
6.
Article in Chinese | WPRIM | ID: wpr-921797

ABSTRACT

Chronical hyperuricemia, a severe metabolic disease characterized by increased serum uric acid, urea nitrogen, and creatinine, has a positive correlation with the risks of gouty arthritis, diabetes, hypertension, and kidney damage. Abnormal purine metabolism and reduced uric acid excretion are the major causes of hyperuricemia, which, thus, points to a potential strategy of preventing from or delaying the progress of hyperuricemia-related diseases and its complications by effectively controlling the serum uric acid level. Increasing evidence has revealed that Chinese medicines alleviate hyperuricemia through regulating intestinal flora, which plays a pivotal role in regulating metabolites, including uric acid level. The disease treatment with traditional Chinese medicine is based on syndrome differentiation, and Chinese medicines often have multiple effects and a wide range of targets. In this review, we summarized the anti-hyperuricemia effects and mechanisms of active compounds in Chinese medicines, single Chinese medicinal herbs, and Chinese medicinal prescriptions in regulating the uric acid level via intestinal flora and metabolites, which will be helpful for further study and application of Chinese medicines in hyperuricemia treatment.


Subject(s)
Arthritis, Gouty , China , Gastrointestinal Microbiome , Humans , Hyperuricemia/drug therapy , Uric Acid
7.
Article in Chinese | WPRIM | ID: wpr-878927

ABSTRACT

The aim of this paper was to investigate the effect of ethanol extract of Phellinus igniarius in lowering uric acid and changing the gut microbiome in hyperuricemia rats. A total of 36 SD rats were randomly divided into normal control group, model control group, positive drug control group, and high-dose, middle-dose and low-dose P. igniarius ethanol extract groups, with 6 rats in each group. Hyperuricemia rats were established by D-fructose combined with oteracil potassium(OAPS). One week later, the positive control group was given allopurinol 50 mg·kg~(-1) intragastrically, and P. igniarius ethanol extract groups were treated with 30, 60 and 90 mg·kg~(-1) drugs for 14 consecutive days. Body weight, blood glucose and serum uric acid(SUA) were monitored every week. After the model rats were administered with the ethanol extracts of P. igniarius by gavage for two weeks, the activities of creatinine, BUN, xanthine oxidase(XOD) and adenosine deaminase(ADA) were detected. The right kidney was taken to analyze the histological and morphological changes and the degree of damage to main organs of the extract of P. igniarius. The 16 S rDNA gene sequence technique was used to analyze the guts microbiota composition in feces. The results indicated that ethanol extract of P. igniarius could significantly lower the SUA level(P<0.01), while inhibiting the activities of XOD and ADA(P<0.05, P<0.01). Histological examination showed that the allopurine group showed slight renal tubular dilation and inflammatory cell infiltration compared with the normal group, with no significant difference between the P. igniarius ethanol extract groups and the normal group. The 16 S sequencing results showed that the composition of gut microbiota has changed in each group. Therefore, ethanol extracts of P. igniarius may reduce the level of SUA in rats by inhibiting the activities of XOD and ADA, with a certain effect on the composition of gut microbiota.


Subject(s)
Animals , Ethanol , Gastrointestinal Microbiome , Hyperuricemia , Phellinus , Plant Extracts , Rats , Rats, Sprague-Dawley , Uric Acid
8.
Rev. Méd. Paraná ; 79(1): 36-39, 2021.
Article in Portuguese | LILACS | ID: biblio-1282395

ABSTRACT

Introdução: A psoríase é uma doença inflamatória crônica, imunomediada, de base genética, com grande polimorfismo de expressão clínica. É caracterizada pelo envolvimento de pele, unhas e, eventualmente, articulações. De ocorrência mundial, possui prevalência entre 2 a 3% na população geral. Entre 20-30% dos pacientes com psoríase desenvolvem a artrite psoriática (AP) a qual pode preceder, estar associada ou suceder o aparecimento da psoríase. A hiperuricemia é uma condição frequentemente associada a pacientes psoriásicos. Objetivos: Estudar a prevalência de hiperuricemia em pacientes com psoríase e sua possível associação com o fenótipo da doença, atividade articular e cutânea. Metodologia: Trata-se de um estudo transversal e analítico realizado através da avaliação de ácido úrico de 58 pacientes diagnosticados com psoríase (com e sem AP) acompanhados pelos ambulatórios de dermatologia e reumatologia do Hospital Universitário Evangélico Mackenzie de Curitiba, PR. Resultados: Cerca de 58 indivíduos foram analisados; dentre eles 24 mulheres e 34 homens, com mediana da idade é de 57 anos. Dos pacientes acometidos pela psoriase, a hiperuricemia esteve presente em 13,7%, sendo mais prevalente no sexo masculino (p=0.01)., nos com artrite psoriásica (p=0.04) e naqueles com envolvimento ungueal (p=0.006) e mais rara naqueles com a forma vulgar da psoríase (p<0.0001). Nenhum paciente apresentou artrite gotosa. A atividade da doença de pele e da doença articular não interferiram nos níveis de ácido úrico (p=ns). Conclusão: Pacientes com artrite psoriásica têm maior incidência de hiperuricemia do que aqueles com psoríase só de pele. Hiperuricemia é mais comum nos pacientes masculinos, com envolvimento ungueal e menos comum naqueles com psoríase vulgar


Introduction: Psoriasis is a chronic, immunomodulated, genetic-based inflammatory disease with great polymorphism of clinical expression. It is characterized by the involvement of skin, nails and eventually joints. It has a worldwide occurrence, with prevalence between 2 and 3% in the general population. Between 20-30% of patients with psoriasis develop psoriatic arthritis (PA), which may precede, be associated with, or succeed psoriasis. Hyperuricemia is a condition often associated with psoriatic patients. Objectives: To study the prevalence of hyperuricemia in patients with psoriasis and its possible association with the phenotype of the disease, joint and skin activity. Methodology: This is a cross-sectional and analytical study conducted through the evaluation of uric acid in patients diagnosed with psoriasis (with and without PA) followed by dermatology and rheumatology outpatient clinics of the Mackenzie Evangelical University Hospital of Curitiba, PR. Results: About 58 individuals were analyzed; among them 24 women and 34 men, with a median age of 57 years. Of the patients affected by psoriasis, hyperuricemia was present in 13.7%, being more prevalent in males (p=0.01), in those with psoriatic arthritis (p=0.04) and in those with nail involvement (p=0.006) and less common in those with the vulgar form of psoriasis (p<0.0001). No patient had gouty arthritis. Skin disease and joint disease activities did not interfere with uric acid levels (p=ns). Conclusion: Patients with psoriatic arthritis have a higher incidence of hyperuricemia than those with skin-only psoriasis. Hyperuricemia is more common in male patients, with nail involvement and less common in those with psoriasis vulgaris


Subject(s)
Humans , Male , Female , Arthritis , Arthritis, Psoriatic , Hyperuricemia
9.
Autops. Case Rep ; 11: e2021328, 2021. graf
Article in English | LILACS | ID: biblio-1339243

ABSTRACT

Background Acute tubulointerstitial nephritis (ATIN) is a very rare paraneoplastic manifestation in patients with multiple myeloma (MM). It is an uncommon pattern of renal disease in such patients. Case presentation We report a case of an 82-year-old male who was admitted with acute kidney injury. Renal biopsy showed typical findings of light chain-associated ATIN with scattered inflammatory cells in the interstitium and associated active tubulitis. No other common manifestations of MM were present at the time of presentation, including hypercalcemia, hyperuricemia, proteinuria, bone pain or lytic bone lesions. Subsequent immunoassays revealed significant serum lambda light chain burden and Bence Jones protein in urine. Immunofluorescence demonstrated linear tubular basement membranes with positive staining for lambda light chain (3+). Electron microscopy (EM) further showed interstitial edema and inflammation. All the aforementioned findings are consistent with ATIN and supported the diagnosis of MM. Conclusions In conclusion, light chain-associated ATIN should be considered in the differential diagnosis of acute interstitial nephritis. Henceforth, serum free light chains as well as serum and urine protein electrophoresis should be included in the workup of such patients.


Subject(s)
Humans , Male , Aged, 80 and over , Multiple Myeloma/complications , Nephritis, Interstitial/complications , Proteinuria , Hyperuricemia , Diagnosis, Differential , Electrophoresis , Acute Kidney Injury , Hypercalcemia
10.
Rev. colomb. cardiol ; 27(5): 394-399, sep.-oct. 2020. tab, graf
Article in English | LILACS, COLNAL | ID: biblio-1289248

ABSTRACT

Abstract Background: Hypertension is responsible for a substantial number of deaths due to cardiovascular disease and stroke. A crucial step toward its control is the identification of modifiable predictors of hypertension. Objectives: To estimate the relationship between salt intake, serum uric acid and incident hypertension in a primary care setting. Methods: Retrospective cohort of the CAMELIA study in which a non-randomized sample of 1098 participants who were ≥ 20 year-old was recruited from a primary care program. Originally, the sample consisted of hypertensive, diabetic and non-diabetic/non-hypertensive subjects. For the analysis, 258 participants with blood pressure (BP) lower than 140/90 mm Hg not using antihypertensive drugs and without diabetes mellitus were included. Five years after the first visit, their medical records were reviewed. Patients were divided into two groups according to BP in the first visit: normal BP group (systolic BP ≤ 120 mm Hg and diastolic BP ≤ 80 mm Hg) and high-normal BP group (systolic BP 121-139 mm Hg and/or diastolic BP 81-89 mm Hg). Results: In multivariate analysis, high-normal BP, hyperuricemia and salt intake ≥ 6 g/day predicted incident hypertension. In participants of thenormal BP group, high salt intake conferred the highest risk. In the high-normal BP group, smoking and serum uric acid were found to be the most important ones. Conclusion: In a healthy, multiethnic, and normotensive population from an urban primary care program, high-normal BP, hyperuricemia and high salt intake were found to be predictors of incident hypertension.


Resumen Antecedentes: La hipertensión es responsable de un gran número de muertes debido a cardiopatías e ictus. Un paso esencial para su control es la identificación de factores modificables predictivos de la hipertensión. Objetivos: Calcular la relación entre ingesta de sal, ácido úrico sérico e hipertensión incidental en un centro de atención primaria. Métodos: Cohorte retrospectiva del estudio CAMELIA, en el que se incluyó una muestra no aleatorizada de 1.098 participantes con edades ≥ 20 años, obtenida de un programa de atención primaria. Originalmente, la muestra incluía sujetos hipertensos, diabéticos y no diabéticos/no hipertensos. Para el análisis, se estudiaron 258 participantes con presión arterial (PA) inferior a 140/90 mm Hg, sin prescripción de fármacos antihipertensivos, y no diabéticos. Transcurridos cinco años de la primera visita, se revisaron sus historias médicas. Se dividió a los pacientes en dos grupos, con arreglo a su PA en la primera visita: grupo con PA normal (PA sistólica ≤ 120 mm Hg y PA diastólica ≤ 80 mm Hg), y grupo con PA alta-normal BP (PA sistólica 121-139 mm Hg y/o PA diastólica 81-89 mm Hg). Resultados: En el análisis multivariante, la PA alta-normal, hiperuricemia e ingesta de sal ≥ 6 g/día predijeron la hipertensión incidental. En los participantes del grupo de PA normal, la ingesta elevada de sal confirió el mayor riesgo. En el grupo de PA alta-normal, el tabaquismo y el ácido úrico sérico fueron los factores más importantes. Conclusión: En una población sana, multiétnica y normotensa, procedente de un programa de atención primaria urbana la PA alta-normal, hiperuricemia e ingesta elevada de sal constituyeron los factores predictivos de la hipertensión incidental.


Subject(s)
Humans , Uric Acid , Stroke , Hyperuricemia , Hypertension , Primary Health Care , Sodium , Incidence , Arterial Pressure
11.
Arch. argent. pediatr ; 118(2): 135-138, abr. 2020. tab
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1100249

ABSTRACT

El daño renal agudo es causa de morbilidad en niños diabéticos en países en vías de desarrollo, especialmente, en pacientes con cetoacidosis diabética. El objetivo de esta investigación fue identificar factores de riesgo para daño renal agudo en pacientes con cetoacidosis diabética. Se realizó un estudio de cohorte retrospectiva. Se incluyeron 50 pacientes diabéticos con cetoacidosis; el 54 % desarrollaron daño renal; en ellos, los niveles de glucosa y ácido úrico fueron mayores (541 mg/dl contra 407 mg/dl, p = 0,014, y 8,13 mg/dl contra 5,72 mg/dl, p = 0,015, respectivamente). El ácido úrico mayor de 6,5 mg/dl demostró un odds ratio de 6,910 (p = 0,027) para daño renal. En conclusión, la hiperuricemia fue un factor de riesgo para el desarrollo de daño renal agudo en estos pacientes. Son necesarios estudios prospectivos para determinar el papel del ácido úrico en la patogénesis del daño renal agudo en pacientes diabéticos.


Acute kidney injury is a cause of morbidity in children with diabetes in developing countries, especially in patients with diabetic ketoacidosis. The objective of this study was to identify the risk factors for acute kidney injury in patients with diabetic ketoacidosis. This was a retrospective cohort study. A total of 50 patients with diabetic ketoacidosis were included; 54 % developed kidney injury. These had higher glucose and uric acid levels (541 mg/dL vs. 407 mg/dL, p = 0.014 and 8.13 mg/dL vs. 5.72 mg/dL, p = 0.015, respectively). Uric acid levels above 6.5 mg/dL showed an odds ratio of 6.910 (p= 0.027) for kidney injury. To conclude, hyperuricemia was a risk factor for acute kidney injury in these patients. Prospective studies are required to determine the role of uric acid in the pathogenesis of acute kidney injury in patients with diabetes.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Diabetic Ketoacidosis/diagnosis , Acute Kidney Injury , Uric Acid , Data Interpretation, Statistical , Retrospective Studies , Risk Factors , Hyperuricemia
12.
Arch. argent. pediatr ; 118(2): s59-s63, abr. 2020. ilus, tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1100502

ABSTRACT

El síndrome de lisis tumoral representa una complicación potencialmente letal provocada por la liberación masiva de ácidos nucleicos, potasio y fosfato hacia la circulación como resultado de la lisis de células neoplásicas, las cuales se caracterizan por una rápida capacidad de proliferación y alta sensibilidad a fármacos. Esto puede ocurrir de forma espontánea antes del inicio del tratamiento y agravarse luego de haberse iniciado la quimioterapia. Presenta una alta mortalidad. Su prevención continúa siendo la medida terapéutica más importante. El cuadro clínico se caracteriza por la existencia de trastornos del metabolismo hidroelectrolítico, en particular, hipercalemia, hiperfosfatemia e hiperuricemia y por la aparición de una lesión renal aguda. Una adecuada intervención terapéutica implica hidratación intravenosa y medidas para prevenir o corregir las alteraciones metabólicas. En este artículo, se proponen lineamientos para seguir tanto en la etapa diagnóstica como en el tratamiento de esta complicación.


The tumor lysis syndrome represents a potentially lethal complication caused by the massive release of nucleic acids, potassium and phosphate into the circulation as a result of the lysis of neoplastic cells, which are characterized by a rapid proliferation capacity and high sensitivity to drugs. This may occur spontaneously prior to the start of treatment, becoming worse after the initiation of chemotherapy. It presents a high mortality; its prevention continues being the most important therapeutic measure. The clinical picture is characterized by the existence of hydroelectrolytic metabolism disorders, in particular hyperkalemia, hyperphosphatemia and hyperuricemia and by the appearance of an acute renal lesion. Adequate therapeutic intervention involves intravenous hydration and measures to prevent or correct metabolic alterations. This article proposes guidelines to follow both in the diagnostic stage and in the treatment of this complication.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Tumor Lysis Syndrome/diagnosis , Tumor Lysis Syndrome/prevention & control , Tumor Lysis Syndrome/drug therapy , Risk Assessment , Hyperuricemia/drug therapy , Hyperphosphatemia/drug therapy , Hypercalcemia/drug therapy , Hypocalcemia/drug therapy
13.
Article in English | WPRIM | ID: wpr-810962

ABSTRACT

BACKGROUND: Although the association of hyperuricemia with an increased risk of mortality has been demonstrated in the context of acute exacerbation of chronic obstructive pulmonary disease (COPD), the long-term outcomes of hyperuricemia have not been studied in the case of stable COPD.METHODS: We retrospectively analyzed baseline data of 240 men with stable COPD enrolled in the Korea Obstructive Lung Disease cohort. We evaluated associations between serum uric acid levels and clinical parameters, risk factors for all-cause mortality, and acute exacerbation of COPD.RESULTS: The mean age of subjects was 66.4 ± 7.7 years, and the median follow-up time was 5.9 years. We identified no significant difference in terms of lung function or laboratory findings between patients with hyperuricemia and those without. Serum uric acid level was negatively associated with systemic inflammation indicated by neutrophil–lymphocyte ratio (r = −0.211, P = 0.001). Univariate Cox regression analysis revealed hyperuricemia to not be associated with an increased risk of all-cause mortality in men with stable COPD (hazard ratio [HR], 0.580; 95% confidence interval [CI], 0.250–1.370; P = 0.213). In the multivariate Cox regression model, hyperuricemia was not an independent predictor of acute exacerbation (HR, 1.383; 95% CI, 0.977–1.959; P = 0.068).CONCLUSION: Among men with stable COPD, hyperuricemia is not an independent predictor of all-cause mortality or future acute exacerbation of COPD. These results differ from those of previous studies on patients with acute exacerbation of COPD.


Subject(s)
Cohort Studies , Follow-Up Studies , Humans , Hyperuricemia , Inflammation , Korea , Lung , Lung Diseases, Obstructive , Male , Mortality , Pulmonary Disease, Chronic Obstructive , Retrospective Studies , Risk Factors , Uric Acid
14.
Article in Chinese | WPRIM | ID: wpr-878812

ABSTRACT

The aim of this paper was to study the specific mechanism of Fangji Huangqi Decoction(FHT) in decreasing uric acid and improving renal function in mice with hyperuricemia(HUA) induced by potassium oxonate, so as to provide theoretical basis for the research and development of drugs for clinical prevention and treatment of HUA and the modernization of traditional Chinese medicine. Sixty Kunming male mice were randomly divided into 6 groups, with 10 mice in each group, namely normal group, model group(250 mg·kg~(-1) potassium oxonate), FHT high, medium and low-dose groups(10 920, 5 460, and 2 730 mg·kg~(-1)) and positive drug allopurinol group(5 mg·kg~(-1)). Drug administration was given once a day for 7 days. On the 6 th day, mice of each group were kept in metabolic cages, and their urine was collected for 24 hours for determination of uric acid, creatinine, and β2-microglobulin(β2-MG) levels. After 7 days, the animals were sacrificed to determine serum uric acid, creatinine β2-MG and interleukin-1β(IL-1β) levels, and their liver and kidney tissues were collected. The liver tissues were used for subsequent determination of xanthine oxidase(XOD) activity, and the kidney tissues were used for subsequent determination of IL-1β levels, pathological tests and related Western blot experiments. In the cell transfection experiment, the cells were divided into blank group, model group(4.8 mmol·L~(-1) uric acid treatment), FHT administration group(4.8 mmol·L~(-1) uric acid+200 μg·mL~(-1) FHT), leucine-rich repeat kinase 1(LRRK1)-small interfering RNA(siRNA) group(4.8 mmol·L~(-1) uric acid+LRRK1-siRNA transfection) and LRRK1-siRNA+FHT group(4.8 mmol·L~(-1) uric acid+LRRK1-siRNA transfection+200 μg·mL~(-1) FHT). After 24 h incubation, the level of IL-1β in the cell supernatant was detected, and the cellular proteins were extracted and used to determine LRRK1, epidermal growth factor receptor(EGFR), PDZ kinase 1(PDZK1) and nuclear factor-kappa B(NF-κB) protein expression levels. The results showed that, FHT could significantly reduce the uric acid, creatinine and β2-MG levels in serum and β2-MG levels in urine, increase the uric acid and creatinine levels in urine, and improve the renal pathological results of the HUA mice, but showed no effect on liver XOD activity; at the same time, we found that the expression level of IL-1β in serum and kidney, NF-κB, LRRK1 and EGFR protein levels in kidney of HUA mice were significantly increased, and the expression level of PDZK1 protein was significantly decreased, while FHT could significantly improve the abnormal expression of these proteins, and FHT increased protein expression of renal organic anion transporter 1(OAT1), OAT3 and ATP bin-ding transporter G2(ABCG2) in HUA mice, but FHT had no effect on the expression of urate transporter 1(URAT1). In the cell transfection experiment, after transfection of LRRK1-siRNA, the levels of IL-1β, EGFR and NF-κB in supernatant were significantly reduced, and the expression of PDZK1 protein was significantly increased. As compared with the LRRK1-siRNA group, the levels of IL-1β, EGFR, PDZK1 and NF-κB did not change significantly with the additional FHT. This study showed that FHT may regulate the renal uric acid transport system through LRRK1 gene, improve the capacity of uric acid excretion, so as to reduce the level of serum uric acid. At the same time, FHT can not only protect the kidney directly, but also in an indirect manner by reducing the level of uric acid.


Subject(s)
Animals , Drugs, Chinese Herbal , Hyperuricemia/drug therapy , Kidney , Male , Mice , Uric Acid
15.
NAJFNR ; 4(7): 268-279, 2020.
Article in English | AIM | ID: biblio-1266919

ABSTRACT

Aim : The main objective of our work was to assess the relationship between type 2 diabetes, hyperuricemia and dyslipidemia in the population of Tizi-Ouzou. By evaluating the relationship between hyperuricemia and some blood lipid parameters, we thus establish, in type 2 diabetes, the correlation between uremia and these lipid parameters. Subjects and methods: The survey was carried out by means of an individual questionnaire. We excluded from our study pregnant women, patients with cancer, patients with end-stage renal disease and subjects who did not respond to the questionnaire. Results: Serum uric acid level increased with age (p = 0.025). Hyperuricemia was associated with heart disease (p = 0.0007). All patients with gout presented an elevated serum uric acid (p = 0.000001). Dyslipidemia was more common in patients with elevated serum uric acid levels (p = 0.0008). Triglyceridemia was significantly associated with hyperuricemia (p = 0.025). The relationship between type 2 diabetes and glomerular filtration rate was not significant, while the latter was decreased in patients with elevated serum uric acid levels (p = 0.0001). In, stratified analysis, age was effect modifier, the age-dependent results make us understand that resistance to insulin constitutes a significant factor of hyperuricemia. Conclusion: The association between hyperuricemia and dyslipidemia in type 2 diabetes emphasizes that insulin resistance acts on both lipid parameters and uricemia. A diet correcting dyslipidemia may also correct the uricemia


Subject(s)
Algeria , Dyslipidemias , Hyperuricemia , Lipoproteins
16.
Rev. cuba. invest. bioméd ; 38(4): e241, oct.-dic. 2019. graf
Article in Spanish | LILACS, CUMED | ID: biblio-1093423

ABSTRACT

.La determinación de la concentración de ácido úrico se realiza con frecuencia en los servicios de salud. Los niveles plasmáticos de ácido úrico se han asociado con las enfermedades cardiovasculares, y con sus factores de riesgo. Sin embargo, la relevancia de esta asociación aún es controvertida, razón por la que se propone fundamentar la relación entre el ácido úrico, el estrés oxidativo y mecanismos involucrados en la enfermedad cardiovascular. Se realizó la búsqueda de la información mediante las bases de datos de diferentes buscadores (Medline-PubMed, Cochrane, Scielo). La hiperuricemia estimula la producción de especies reactivas oxidantes intracelulares y la reacción del ácido úrico con el óxido nítrico se relaciona con la disfunción endotelial y la resistencia a la insulina. Los niveles de ácido úrico se asocian con la hipertensión arterial, la diabetes mellitus, el síndrome metabólico y la enfermedad cardiovascular. Se considera además, que el ácido úrico es un factor de riesgo independiente para eventos cardiovasculares y un predictor de la morbilidad y la mortalidad por estas enfermedades, aunque se requiere de estudios de intervención con hipouricémicos o uricosúricos para el análisis de los beneficios que pudiera representar modificar la concentración de ácido úrico en sangre en determinadas condiciones(AU)


. The determination of the concentration of uric acid is often performed in health services. Plasma uric acid levels have been associated with cardiovascular diseases, and with their risk factors. However, the relevance of this association is still controversial, which is why it is proposed to base the relationship between uric acid, oxidative stress and mechanisms involved in cardiovascular disease. The information was searched through the databases of different search engines (Medline-PubMed, Cochrane, Scielo). Hyperuricemia stimulates the production of intracellular oxidizing reactive species and the reaction of uric acid with nitric oxide is related to endothelial dysfunction and insulin resistance. Uric acid levels are associated with high blood pressure, diabetes mellitus, metabolic syndrome and cardiovascular disease. It is also considered that uric acid is an independent risk factor for cardiovascular events and a predictor of morbidity and mortality from these diseases, although intervention studies with hypouricemic or uricosuric tests are required for the analysis of the benefits that could represent modify the concentration of uric acid in blood under certain conditions(AU)


Subject(s)
Humans , Uric Acid , Insulin Resistance , Cardiovascular Diseases , Metabolic Syndrome , Hyperuricemia , Nitric Oxide
17.
Säo Paulo med. j ; 137(6): 523-529, Nov.-Dec. 2019. tab
Article in English | LILACS | ID: biblio-1094520

ABSTRACT

ABSTRACT BACKGROUND: Findings regarding the effects of hyperuricemia on renal function and mortality have been inconsistent. OBJECTIVES: To investigate the effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease (CKD). DESIGN AND SETTING: Retrospective cohort study conducted in a medical center in Taiwan. METHODS: Patients with CKD in stages 3-5, without histories of renal replacement therapy, were consecutively recruited from 2007 to 2013. Their medical history, laboratory and medication data were collected from hospital records. The mean uric acid level in the first year of follow-up was used for analyses. Hyperuricemia was defined as mean uric acid level ≥ 7.0 mg/dl in men or ≥ 6.0 mg/dl in women. The primary outcomes were incident renal replacement therapy and all-cause mortality, and these data were retrospectively collected from hospital records until the end of 2015. RESULTS: A total of 4,381 patients were analyzed (mean age 71.0 ± 14.8 years; males 62.7%), and the median follow-up period was 2.5 years. Patients with hyperuricemia were at increased risk of incident renal replacement therapy and all-cause mortality, especially those with CKD in stages 4 or 5. Compared with patients with CKD in stage 3 and normouricemia, patients with CKD in stages 4 or 5 presented significantly higher risk of all-cause mortality only if they had hyperuricemia. CONCLUSIONS: In patients with CKD in stages 3-5, hyperuricemia was associated with higher risk of incident renal replacement therapy and all-cause mortality. Whether treatment with uric acid-lowering drugs in these patients would improve their outcomes merits further investigation.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Renal Replacement Therapy , Hyperuricemia/blood , Renal Insufficiency, Chronic/blood , Uric Acid/analysis , Severity of Illness Index , Proportional Hazards Models , Retrospective Studies , Risk Factors , Follow-Up Studies , Hyperuricemia/complications , Hyperuricemia/physiopathology , Hyperuricemia/mortality , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/physiopathology , Renal Insufficiency, Chronic/mortality , Glomerular Filtration Rate
18.
Rev. Assoc. Med. Bras. (1992) ; 65(9): 1155-1160, Sept. 2019. tab, graf
Article in English | LILACS | ID: biblio-1041075

ABSTRACT

SUMMARY OBJECTIVE In this study, we aimed to analyze the relationship between serum uric acid (UA) and microalbuminuria as a marker of renal injury in type 2 diabetes mellitus. METHODS A total of 100 patients with type 2 diabetes mellitus were enrolled in the study. Participants were divided into two groups according to the urinary microalbumin/creatinine ratio: diabetic nephropathy and non-nephropathy group. UA and microalbuminuria were compared between the study groups. RESULTS Serum UA levels of diabetic nephropathy patients were significantly higher than those in the non-nephropathy group (UA in patients with diabetic nephropathy groups: 6.3 (1.82) mg/dl, UA in patients of the non-nephropathic group: 4.85 (1.92) mg/dl) (p<0.001). There was a correlation between microalbuminuria and UA (r=0.238). This correlation was statistically significant (p=0.017). CONCLUSION UA levels may be an important predictor of nephropathy in diabetic patients.


RESUMO OBJETIVO O objetivo deste estudo foi analisar a relação entre o ácido úrico sérico e a microalbuminúria como marcador de lesão renal no diabetes mellitus tipo 2. MÉTODOS Um total de 100 pacientes com diabetes mellitus tipo 2 foram inscritos no estudo. Os grupos de estudo foram divididos em dois, de acordo com a relação microalbumina/creatinina na urina: nefropatia diabética e grupo não nefropático. UA e microalbuminúria foram comparados entre os grupos de estudo. RESULTADOS Os níveis séricos de AU de pacientes com nefropatia diabética foram significativamente maiores do que o grupo sem nefropatia (AU em pacientes com grupos de nefropatia diabética: 6,3 (1,82) mg/dl, AU em pacientes com grupos não nefropáticos: 4,85 (1,92) mg/dl ) (p<0,001). Houve correlação entre microalbuminúria e AU (r=0,238). Essa correlação foi estatisticamente significativa (p=0,017). CONCLUSÃO Os níveis de AU podem ser um importante preditor de nefropatia em pacientes diabéticos.


Subject(s)
Humans , Male , Female , Aged , Uric Acid/blood , Hyperuricemia/complications , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/etiology , Biomarkers/blood , Retrospective Studies , Sensitivity and Specificity , Creatinine/urine , Diabetes Mellitus, Type 2/blood , Diabetic Nephropathies/blood , Albuminuria/urine , Glomerular Filtration Rate , Middle Aged
19.
Gac. méd. Méx ; 155(3): 236-242, may.-jun. 2019. tab
Article in English, Spanish | LILACS | ID: biblio-1286498

ABSTRACT

Resumen Introducción: La hiperuricemia es un factor de riesgo para enfermedad cardiovascular, pero su impacto no ha sido bien documentado. Objetivo: Evaluar el impacto de la hiperuricemia en los parámetros metabólicos y los factores de riesgo cardiovascular en mexicanos aparentemente sanos. Método: Estudio trasversal de 768 adultos jóvenes. Se buscó asociación de la hiperuricemia con alteraciones de los parámetros metabólicos y factores de riesgo cardiovascular (hipertensión, dislipidemia mixta y síndrome metabólico). Se aplicaron modelos loglineales y de regresión para determinar la influencia de la hiperuricemia. Se aplicó análisis multivariado de varianza para observar la interacción de la hiperuricemia y el sobrepeso u obesidad en los cambios de los parámetros metabólicos. Resultados: Los parámetros metabólicos fueron mayores en los individuos con hiperuricemia que con ácido úrico normal (< 0.05). La hiperuricemia se asoció significativamente con hipertensión (RM = 6.8, IC 95 % = 1.1-46), dislipidemia (RM = 2.5, IC 95 % = 1.3-4.7) y síndrome metabólico (RM = 2.3, IC 95 % = 1.1-4.6). La hiperuricemia y el sobrepeso u obesidad predicen significativamente los cambios en los parámetros metabólicos de riesgo cardiovascular (l de Wilks = 0.91, F [6.175] = 3.1, p = 0.007). Conclusiones: La hiperuricemia está asociada significativamente con las alteraciones metabólicas y los distintos factores de riesgo cardiovascular.


Abstract Introduction: Hyperuricemia is a risk factor for cardiovascular disease, but its impact has not been properly documented. Objective: To assess the impact of hyperuricemia on metabolic parameters and cardiovascular risk factors (CRF) in apparently healthy Mexicans. Method: Cross-sectional study of 768 young adults. Association of hyperuricemia with alterations in metabolic parameters and CRF (hypertension, mixed dyslipidemia, metabolic syndrome) was sought. Log-linear and regression models were used to determine the influence of hyperuricemia. A multivariate analysis of variance was applied to observe the interaction of hyperuricemia and overweight or obesity with changes in metabolic parameters. Results: Metabolic parameters were higher in patients with hyperuricemia than with normal uric acid (all < 0.05). Hyperuricemia was significantly associated with hypertension (OR=6.8, 95 % CI: 1.1-46), dyslipidemia (OR=2.5, 95% CI: 1.3-4.7) and metabolic syndrome (OR=2.3, 95% CI: 1.1-4.6). Hyperuricemia and overweight or obesity significantly predict changes in cardiovascular risk metabolic parameters (Wilks’ l=0.91, F (6.175)=3.1, p=0.007). Conclusions: Hyperuricemia is significantly associated with metabolic alterations and different CRF.


Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Cardiovascular Diseases/etiology , Metabolic Syndrome/epidemiology , Hyperuricemia/complications , Dyslipidemias/epidemiology , Hypertension/epidemiology , Cardiovascular Diseases/epidemiology , Cross-Sectional Studies , Risk Factors , Overweight/complications , Mexico/epidemiology , Obesity/complications
20.
Medisan ; 23(1)ene.-feb. 2019. graf
Article in Spanish | LILACS | ID: biblio-990183

ABSTRACT

Se presenta el caso clínico de un paciente de 57 años de edad, mestizo, con antecedentes de artritis reumatoidea y gota, quien acude a la consulta especializada de Dermatología del Hospital Clinicoquirúrgico Docente Celia Sánchez Manduley de Manzanillo, provincia de Granma, por presentar lesiones nodulares dolorosas diseminadas. Se realizaron estudios complementarios y biopsia de piel, cuyos resultados permitieron diagnosticar una gota tofácea crónica. El paciente llevaba tratamiento medicamentoso con prednisona, colchicina y metrotexate, pero luego de discutir el caso con los especialistas en medicina interna y reumatología se decidió sustituir la colchicina por el alopurinol.


The case report of a 57 year-old mestizo patient, is presented with a history of rheumatoid arthritis and gout who visited the specialized Dermatology department of Celia Sánchez Manduley Teaching Clinical-Surgical Hospital in Manzanillo, Granma province, for presenting disseminated painful nodular lesions. Complementary studies and skin biopsy were carried out which results allowed to diagnose a chronic . The patient was under drugs treatment with prednisona, colchicina and metrotexate, but after discussing the case with the specialists in internal medicine and rheumatology it was decided to sustitute colchicina by alopurinol.


Subject(s)
Humans , Male , Middle Aged , Arthritis, Gouty/diagnosis , Hyperuricemia , Gout , Uric Acid/metabolism , Secondary Care
SELECTION OF CITATIONS
SEARCH DETAIL